Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Bodegard

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Atherosclerosis|November 9, 2011
HDL-cholesterol and prediction of coronary heart disease: modified by physical fitness? A 28-year follow-up of apparently healthy menPer Torger Skretteberg, Irene Grundvold, Sverre E Kjeldsen, et al.
Journal of Hypertension|October 17, 2018
SBP above 180 mmHg at moderate exercise workload increases coronary heart disease risk in healthy men during 28-year follow-upJulian E Mariampillai, Erik E Prestgaard, Sverre E Kjeldsen, et al.
Hypertension (Dallas, Tex. : 1979)|November 19, 2019
Exercise Systolic Blood Pressure at Moderate Workload Is Linearly Associated With Coronary Disease Risk in Healthy MenJulian E Mariampillai, Knut Liestøl, Sverre E Kjeldsen, et al.
European Journal of Preventive Cardiology|August 15, 2018
Physical fitness is a modifiable predictor of early cardiovascular death: A 35-year follow-up study of 2014 healthy middle-aged menKristian Engeseth, Erik E Prestgaard, Julian E Mariampillai, et al.
Diabetes, Obesity & Metabolism|December 12, 2018
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational studyKåre I Birkeland, Johan Bodegard, Anna Norhammar, et al.
Diabetes, Obesity & Metabolism|August 4, 2017
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational studyFrederik Persson, Thomas Nyström, Marit E Jørgensen, et al.
Heart (British Cardiac Society)|February 13, 2023
Prevalence, outcomes and costs of a contemporary, multinational population with heart failureAnna Norhammar, Johan Bodegard, Marc Vanderheyden, et al.
The Lancet Regional Health. Europe|September 12, 2022
Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD studyJohan Sundström, Johan Bodegard, Andreas Bollmann, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational studyFrederik Persson, Johan Bodegard, Jorma T Lahtela, et al.
Diabetes, Obesity & Metabolism|September 7, 2020
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational studyKåre I Birkeland, Johan Bodegard, Amitava Banerjee, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Atherosclerosis|November 9, 2011
HDL-cholesterol and prediction of coronary heart disease: modified by physical fitness? A 28-year follow-up of apparently healthy menPer Torger Skretteberg, Irene Grundvold, Sverre E Kjeldsen, et al.
Journal of Hypertension|October 17, 2018
SBP above 180 mmHg at moderate exercise workload increases coronary heart disease risk in healthy men during 28-year follow-upJulian E Mariampillai, Erik E Prestgaard, Sverre E Kjeldsen, et al.
Hypertension (Dallas, Tex. : 1979)|November 19, 2019
Exercise Systolic Blood Pressure at Moderate Workload Is Linearly Associated With Coronary Disease Risk in Healthy MenJulian E Mariampillai, Knut Liestøl, Sverre E Kjeldsen, et al.
European Journal of Preventive Cardiology|August 15, 2018
Physical fitness is a modifiable predictor of early cardiovascular death: A 35-year follow-up study of 2014 healthy middle-aged menKristian Engeseth, Erik E Prestgaard, Julian E Mariampillai, et al.
Diabetes, Obesity & Metabolism|December 12, 2018
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational studyKåre I Birkeland, Johan Bodegard, Anna Norhammar, et al.
Diabetes, Obesity & Metabolism|August 4, 2017
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational studyFrederik Persson, Thomas Nyström, Marit E Jørgensen, et al.
Heart (British Cardiac Society)|February 13, 2023
Prevalence, outcomes and costs of a contemporary, multinational population with heart failureAnna Norhammar, Johan Bodegard, Marc Vanderheyden, et al.
The Lancet Regional Health. Europe|September 12, 2022
Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD studyJohan Sundström, Johan Bodegard, Andreas Bollmann, et al.
Endocrinology, Diabetes & Metabolism|March 1, 2019
Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational studyFrederik Persson, Johan Bodegard, Jorma T Lahtela, et al.
Diabetes, Obesity & Metabolism|September 7, 2020
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational studyKåre I Birkeland, Johan Bodegard, Amitava Banerjee, et al.
Pageof 5